Overview
This program will provide an up-to-date, comprehensive review of the management of squamous cell non-small lung cancer. With the introduction of the immune checkpoint inhibitors into current treatment algorithms, it is timely to address the new treatment paradigms for squamous NSCLC and the impact upon clinical practice.
After attending this session, attendees will be able to:
- Illustrate awareness of recently completed and ongoing clinical trials in squamous cell lung cancer.
- Recognize of treatment paradigms incorporating immune checkpoint inhibitor therapies.
- Assess knowledge in the decision-making process in the management of patients with squamous cell carcinoma.
Corey J. Langer MD, FACP
Director of Thoracic Oncology, Abramson Cancer Center, Professor of Medicine, University of Pennsylvania.
For any inquiries, please contact meetings@iaslc.org.
After attending this session, attendees will be able to:
- Illustrate awareness of recently completed and ongoing clinical trials in squamous cell lung cancer.
- Recognize of treatment paradigms incorporating immune checkpoint inhibitor therapies.
- Assess knowledge in the decision-making process in the management of patients with squamous cell carcinoma.
Corey J. Langer MD, FACP
Director of Thoracic Oncology, Abramson Cancer Center, Professor of Medicine, University of Pennsylvania.
For any inquiries, please contact meetings@iaslc.org.